FDA Clears Takeda's New Narcolepsy Pill Orzeyful, Expanding Treatment Options
The U.S. Food and Drug Administration has approved Takeda's twice-daily drug Orzeyful, an orexin receptor agonist for narcolepsy type 1.
The Food and Drug Administration approved a new oral therapy from Takeda called Orzeyful, designed for narcolepsy type 1 patients who lack orexin neurons. Orzeyful is an orexin receptor agonist administered twice daily, representing a different drug class from traditional stimulants and sodium oxybates. Phase 3 clinical studies showed that users remained awake for significantly longer periods, experienced less daytime sleepiness, fewer cataplexy attacks, and greater attentiveness.
Existing options are limited by potential for abuse and incomplete symptom control. The approval is expected to broaden the therapeutic landscape for sleep-related neurologic disorders.
Why it matters
A new FDA-approved drug offers narcolepsy patients a potentially safer and more effective treatment option.
In this story